Loqtorzi significantly improved progression-free and overall survival in HER2-expressing advanced urothelial carcinoma compared to chemotherapy. The study demonstrated a higher overall response rate ...
Enhertu significantly improved overall survival and progression-free survival compared to Cyramza plus paclitaxel in HER2-positive metastatic GC/GEJ patients. The DESTINY-Gastric04 trial established ...
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical ...
Real-world Roswell Park analysis links T-DXd to improved long-term overall survival versus standard chemotherapy in ...
DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals (JAZZ) plc today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating ...
Overall survival (OS): The arm in which Tevimbra was added to Ziihera and chemotherapy resulted in a statistically significant improvement in OS (median OS of 26.4 months) at IA1. The Ziihera plus ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...
Zanidatamab plus chemotherapy with or without tislelizumab significantly improves progression free survival in first-line ...
– The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...
Discover how advancements in HER2-positive breast cancer treatment enhance patient outcomes through personalized therapies and innovative strategies for both early and metastatic stages. Over the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results